Breast Cancer In Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From An Argentine National Database

PURPOSE Multiple studies have reported that breast cancer in young patients is associated with aggressive characteristics, and it is suggested that prognosis is worse independently of pathologic variables.PATIENTS AND METHODS We performed a retrospective analysis of the Breast Cancer Registry of the Argentinian Society of Mastology, including public and private centers. Patients <= 40 years of age at diagnosis were classified as "young," and patients <= 35 years of age at diagnosis were classified as "very young." Univariate and multivariate analyses were performed to detect differences between groups.RESULTS Patients <= 40 years of age comprised 10.40% (739/7,105) of the participants, with an average age of 35.61 4.04 years. Multivariate analysis showed that human epidermal growth factor receptor 2 (HER2)-positive tumor phenotype (odds ratio [OR], 1.82), nodal involvement (OR, 1.69), histologic grade (grade 3 OR, 1.41), and tumor size (T2 OR, 1.37; T3-T4, 1.47) were independently associated with younger age at diagnosis. Patients <= 35 years of age (n = 286), compared with patients 36 to 40 years of age, had a higher proportion of HER2 tumors (24.58% v 16.94%; P = .021), absence of progesterone receptor expression (29.85% v 22.95%; P = .043), and stage 3 cancer (29.34% v 18.52%; P < .001). Fewer breast-conserving surgeries (75.37% v 62.89%; P < .001) and more adjuvant chemotherapy (59.04% v 36.66%; P < 0.001) were reported in patients <= 40 years of age.CONCLUSION In the population studied, breast cancer in young women was associated with aggressive pathologic features and locally advanced disease at the time of diagnosis. Moreover, tumor characteristics in very young patients with breast cancer nested in the population <= 40 years of age showed differences in important prognostic factors. More high-quality evidence is needed to improve treatment strategies in these patients. (c) 2020 by American Society of Clinical Oncology